Government Plan to Expand Medicare HIV Coverage Is Dropped

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 1
Volume 7
Issue 1

WASHINGTON-The Clinton administration has decided not to extend Medicaid coverage to all low-income people infected with HIV. Currently, HIV-positive patients who have developed AIDS can receive Medicaid benefits even if they are not poor enough to qualify under normal Medicaid guidelines.

WASHINGTON—The Clinton administration has decided not to extend Medicaid coverage to all low-income people infected with HIV. Currently, HIV-positive patients who have developed AIDS can receive Medicaid benefits even if they are not poor enough to qualify under normal Medicaid guidelines.

The administration had speculated that extending the AIDS exception would be cost effective by allowing HIV-positive patients to receive the newer HIV drug combinations that may prevent progression to AIDS.

However, Victor Zonana, a spokesman for the Department of Health and Human Services, said that none of the proposals for the expansion analyzed by the government yielded a “revenue-neutral” plan, that is, one that would not increase spending over a 5-year period.

Although the administration has declined to make the change nationwide, individual states have the option of developing and submitting their own proposals for such a change, if they can be shown not to increase costs. According to Mr. Zonana, at least three states—Maine, Massachusetts, and Florida—have expressed an interest in doing so.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content